Biogen wins European first for depression drug Zurzuvae0 SHARESPosted: 19 September 2025 | Catherine Eckford (European Pharmaceutical Review) |The medicine becomes the first EU-approved oral treatment for adults who have postpartum depression (PPD). The European Commission (EC) has authorised Biogen’s Zurzuvae (zuranolone) for women with post-partum depression (PPD), making it the first oral treatment for the condition to be licensed in Europe. Dr Priya Singhal, Head of Development at Biogen, remarked that the new approval “is a major milestone in addressing a critical unmet need in maternal health for women in Europe, where postpartum depression is underdiagnosed and undertreated”. [Zurzuvae] can improve the symptoms of [postpartum depression] as early as day three. Bringing Zurzuvae to marketZurzuvae won approval in August 2023 from the US Food and Drug Administration (FDA) and last month the Medicines and Healthcare products Regulatory Agency (MHRA) authorised the drug in the UK.